More than meets the eye: the ACCORD trial and use of statin‐fibrate combination in type 2 diabetes mellitus

Abstract

powerful predictor of cardiovascular disease (CVD) in type 2 diabetes, with low-density lipoprotein (LDL) being the most atherogenic lipoprotein. Accordingly, the first priority of lipid-regulating treatment is to lower the plasma concentration of LDL-cholesterol. This is efficaciously achieved with a statin, as evidenced by several excellent clinical endpoint trials.1 While the importance of correcting hyperglycaemia is well established, the significance of dyslipidaemia and its treatment for preventing progression of diabetic microangiopathy, particularly retinopathy, remains undefined.